Qilu Pharmaceuticals" Malay acid afatini tablets were approved for sale.

On September 3, Qilu Pharmaceuticals submitted a new class of 4 generic drug Malay acid afatinib tablets approved by the State Drug Administration for listing, the second domestic company after Haussen approved the product for listing.
Afatini belongs to the second generation of EGFR-TKI, developed by Grigg Ingham.
unlike the first generation of reversible EGFR TKI, afatinib irreversibly binds to EGFR to close the cell signaling path and inhibit tumor growth.
approved by the FDA in July 2013 and entered China in February 2017 for first-line/second-line treatment of non-small cell lung cancer that is positive for EGFR mutations.
September 2018, Afadini negotiated access to the National Health Insurance Category B.
EGFR gene mutation is the most common type of gene mutation in patients with non-small cell lung cancer in China, accounting for about 50%.
a total of 8 EGFR-TKI approved for listing worldwide, of which Giffeitini in China has been included in the volume procurement, Qilu Pharmaceuticals successfully won the bid.
Haussen Pharmaceuticals' Afatini has been the first to be approved for listing in China in June 2020, and the Pharmaceutical Rubik's Cube database NextPharma shows that there are currently six manufacturers in China that have submitted Afadinib listing applications under the new four categories, including Shi Pharmaceutical Group, Yangzijiang, Zhengda Tianqing and Colum Pharmaceuticals.
name source: Medical Rubik's Cube !-- end of content display -- !-- whether the login ends.